R. Lahti

发表

Comparison of 5-HT1A and dopamine D2 pharmacophores. X-ray structures and affinities of conformationally constrained ligands.

C. Chidester, C. Lin, R. Lahti, 1993, Journal of medicinal chemistry.

D2-Family receptor distribution in human postmortem tissue: an autoradiographic study

C. Tamminga, R. Roberts, R. Lahti, 1995, Neuroreport.

Rapid separation of enkephalins and endorphins on Sep-Pak reverse phase cartridges.

R. Lahti, D. Gay, 2009, International journal of peptide & protein research.

Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications.

D. Evans, R. Lahti, N. Stratman, 1993, European journal of pharmacology.

U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.

R. Lahti, J. H. Ludens, P. Vonvoigtlander, 1983, The Journal of pharmacology and experimental therapeutics.

Therapeutic implications of dopamine D4 vs. D2 receptor selectivity and occupancy

C. Tamminga, D. Evans, R. Lahti, 1993, European Neuropsychopharmacology.

Lack of effect of des-tyrosine1-γ-endorphin on in vivo [3H]spiperone binding

R. Lahti, 1982 .

CYCLIC AMP AND PHOSPHODIESTERASE IN SYNAPTIC VESICLES FROM MOUSE BRAIN

R. Lahti, G. Johnson, S. J. Boukma, 1973, Journal of neurochemistry.

[Norleucine3,6]-Substituted Cholecystokinin Octapeptide Analogues

S. Bunting, T. Sawyer, R. Lahti, 1986 .

A new 21-aminosteroid antioxidant lacking glucocorticoid activity stimulates adrenocorticotropin secretion and blocks arachidonic acid release from mouse pituitary tumor (AtT-20) cells.

E. Hall, R. Lahti, V. Sethy, 1988, The Journal of pharmacology and experimental therapeutics.

U-50488H, a pure kappa receptor agonist with spinal analgesic loci in the mouse.

M. Piercey, R. Lahti, C. Barsuhn, 1982, Life sciences.

U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia.

E. Hall, R. Lahti, E. Jacobsen, 1991, The Journal of pharmacology and experimental therapeutics.

Evidence for a central sympathoexcitatory action of alpha-2 adrenergic antagonists.

R. Mccall, R. Lahti, C. Barsuhn, 1983, The Journal of pharmacology and experimental therapeutics.

[3H]U-69593 a highly selective ligand for the opioid κ receptor

J. Mccall, R. Lahti, M. M. Mickelson, 1985 .

Effect Of amphetamine, α-Methyl-P-tyrosine (α-MPT) and antipsychotic agents on dopamine D2-type receptor occupancy in rats

C. Tamminga, R. Lahti, 1999, Progress in Neuro-psychopharmacology and Biological Psychiatry.

Affinities and intrinsic activities of dopamine receptor agonists for the hD21 and hD4.4 receptors.

H. Wikström, C. Tamminga, R. Lahti, 1996, European journal of pharmacology.

Growth of Chinese hamster ovary (CHO) cells expressing the 5-HT2 serotonin receptor in suspension culture: an efficient method for large-scale acquisition of membrane protein for drug evaluation

D. Evans, R. Lahti, P. Zaworski, 1995, Journal of Neuroscience Methods.

Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities.

D. Evans, P. Ruppel, R. Lahti, 1992, Molecular pharmacology.

P-9-1 Differing properties of dopamine agonists and partial agonists at the cloned human D21 and D4.4 receptors

C. Tamminga, A. Lahti, R. Lahti, 1996, European Neuropsychopharmacology.

[3H]Neurotensin receptor densities in human postmortem brain tissue obtained from normal and schizophrenic persons. An autoradiographic study

R. Conley, C. Tamminga, R. Roberts, 1998, Journal of Neural Transmission.

[3H]U-69593 a highly selective ligand for the opioid kappa receptor.

J. Mccall, R. Lahti, P. von Voigtlander, 1985, European journal of pharmacology.

The effect of minor tranquilizers on stress-induced increases in rat plasma corticosteroids

R. Lahti, C. Barsuhn, 1974, Psychopharmacologia.

Pre- and postsynaptic dopaminergic activities of U-86170F

D. Evans, R. Lahti, R. Huff, 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.

Novel antidopaminergic strategies for the treatment of schizophrenia

C. Tamminga, A. Lahti, R. Lahti, 1995, Schizophrenia Research.

Properties of a selective kappa agonist, U-50,488H.

R. Lahti, C. Barsuhn, P. Vonvoigtlander, 1982, Life sciences.

3H-SKF10047 receptor binding studies. Attempts to define the opioid sigma receptor

R. Lahti, M. M. Mickelson, 1984, Neuropeptides.

Inhibition of [H3]serotonin uptake by the mouse spleen. A structure-activity study.

R. Lahti, P. A. Platz, B. McAllister, 1970, Journal of medicinal chemistry.

Inhibition of 3H-spiroperidol binding by an endogenous material from brain.

R. Lahti, C. Barsuhn, D. Gay, 1978, European journal of pharmacology.

Chapter 1. Antidepressants and Antipsychotic Agents

R. Lahti, 1977 .

In vivo [3H]-spiperone binding. The locus of action of antipsychotic agents

R. Lahti, 1987 .

D2-family receptors in schizophrenia: Distribution and implications for treatment

R. Wise, C. Tamminga, A. Lahti, 1995 .

Chronic naloxone results in prolonged increases in opiate binding sites in brain.

R. Collins, R. Lahti, R. James Collins, 1978, European journal of pharmacology.

Factors Affecting Binding of trans‐N‐[2‐(Methylamino)cyclohexyl]benzamides at the Primary Morphine Receptor.

D. Zichi, R. Lahti, B. Cheney, 1986 .

Factors affecting binding of trans-N-[2-(methylamino)cyclohexyl]benzamides at the primary morphine receptor.

D. Zichi, R. Lahti, B. Cheney, 1985, Journal of medicinal chemistry.

Novel anxiolytic agents derived from alpha-amino-alpha-phenyl-o-tolyl-4H-triazoles and -imidazoles.

C. Chidester, R. Lahti, D. Duchamp, 1978, Journal of medicinal chemistry.

Conversion of N-alkylaminobenzophenones to benzodiazepines in vivo.

R. Lahti, M. Gall, 1976, Journal of medicinal chemistry.

Synthesis and pharmacology of novel anxiolytic agents derived from 2-[(dialkylamino)methyl-4H-triazol-4-yl] benzophenones and related heterocyclic benzophenones.

R. Lahti, M. Gall, J. Hester, 1976, Journal of medicinal chemistry.

(S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist.

R. Lahti, M. Smith, S A Rees, 1996, Journal of medicinal chemistry.

4-Aminomethyl chromans: dependence of serotonin and dopamine binding upon aromatic ring substitution

R. Lahti, M. D. Ennis, R. Hoffman, 1993 .

Antipsychotic Properties of the Partial Dopamine Agonist (−)-3-(3-Hydroxyphenyl)-N-n-Propylpiperidine (Preclamol) in Schizophrenia

C. Tamminga, A. Lahti, A. Carlsson, 1998, Biological Psychiatry.

The tricyclic antidepressants--inhibition of norepinephrine uptake as related to potentiation of norepinephrine and clinical efficacy.

R. P. Maickel, R. Lahti, 1971, Biochemical pharmacology.

Acetaldehyde--an inhibitor of the enzymatic oxidation of 5-hydroxyindoleacetaldehyde.

R. Lahti, E. Majchrowicz, 1969, Biochemical pharmacology.

The effects of acetaldehyde on serotonin metabolism.

R. Lahti, E. Majchrowicz, 1967, Life sciences.

Comparative neuroanatomical distribution of the kappa and mu opioid receptors in guinea pig brain sections.

J. Mccall, R. Lahti, K. Jodelis, 1989, European journal of pharmacology.

Antidepressant and antipsychotic agents

R. Lahti, 1979, Naturwissenschaften.

Structure-activity relationships of enkephalins containing serially replaced thiomethylene amide bond surrogates.

A. Spatola, R. Lahti, P. von Voigtlander, 1986, Life sciences.

Evaluation of naloxone for therapy of Escherichia coli shock. Species differences.

A. Chang, L. Hinshaw, R. Lahti, 1984, Archives of surgery.

Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: a [3H]NGD-94-1 study

R. Conley, C. Tamminga, R. Roberts, 1998, Molecular Psychiatry.

D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects.

R. Conley, C. Tamminga, R. Roberts, 1996, Neuroreport.

Distribution of dopamine D4 receptor in human postmortem brain sections: Autoradiographic studies with [3H]-NGD-94-1

C. Tamminga, R. Roberts, D. Gallager, 1996, Schizophrenia Research.

Ethanol and acetaldehyde effects on metabolism and binding of biogenic amines.

R. Lahti, E. Majchrowicz, 1974, Quarterly journal of studies on alcohol.

Dopamine D2, D3, D4 receptors in human postmortem brain sections: Comparison between normals and schizophrenics

R. Conley, C. Tamminga, R. Roberts, 1996, Schizophrenia Research.

The metabolism of biogenic amines in experimental animals and in human subjects during acute and chronic administration of ethanol.

R. Lahti, F. Karoum, E. Majchrowicz, 1977, Advances in experimental medicine and biology.

Alcohol, aldehydes and biogenic amines.

R. Lahti, 1975, Advances in experimental medicine and biology.

Effects of α-methyl-5-hydroxytryptophan and α-methyl-5-hydroxytryptamine on norepinephrine in mouse myocardium

R. Lahti, R. V. Heinzelman, P. A. Platz, 1969 .

Effect of a butyrophenone derivative, U-32,802A, on brain biogenic amines.

D. Lednicer, R. Lahti, 1974, Biochemical pharmacology.

Selective protection of serotonin stores against the action of reserpine by -methyl-5-hydroxytryptpohan pretreatment.

R. Lahti, P. A. Platz, 1969, Biochemical pharmacology.

Effect of α-methyl-5-hydroxytryptophan ethyl ester upon tissue norepinephrine levels in rats and mice

T. L. Lemke, R. Lahti, G. Johnson, 1969 .

Antagonism of kainic acid lesions in the mouse hippocampus by U-54494A and U-50488H.

R. Lahti, G. M. Strain, P. von Voigtlander, 1992, Life sciences.

Apomorphine antagonism of the elevation of homovanillic acid induced by antipsychotic drugs.

R. Lahti, B. McAllister, J. Wozniak, 1972, Life sciences. Pt. 1: Physiology and pharmacology.

Opiate effects on plasma corticosteriods: relationship to dysphoria and self-administration

R. Collins, R. Lahti, 1982, Pharmacology Biochemistry and Behavior.

Ethanol and acetaldehyde effects on metabolism and binding of biogenic amines.

R. Lahti, E. Majchrowicz, 1974, Quarterly journal of studies on alcohol.

Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine

R. Lahti, V. Sethy, C. Barsuhn, 1983, Neuropharmacology.

Drug affinities for the agonist and antagonist states of the opioid receptor.

R. Lahti, C. Barsuhn, B. Cheney, 1982, European journal of pharmacology.

Dopamine D2 receptor binding properties of [3H]U-86170, a dopamine receptor agonist.

D. Evans, R. Lahti, L. Figur, 1991, European journal of pharmacology.

Stimulating and inhibitory effects of the dopamine “stabilizer” (−)-OSU6162 on dopamine D2 receptor function in vitro

C. Tamminga, A. Carlsson, R. Lahti, 2007, Journal of Neural Transmission.

Rapid communication Stimulating and inhibitory effects of the dopamine ''stabilizer'' (2)-OSU6162 on dopamine D2 receptor function in vitro

C. Tamminga, A. Carlsson, R. Lahti, 2007 .

Centrally acting serotonergic and dopaminergic agents. 1. Synthesis and structure-activity relationships of 2,3,3a,4,5,9b-hexahydro-1H-benz[e]indole derivatives.

M. Piercey, R. Mccall, C. Chidester, 1993, Journal of Medicinal Chemistry.

The effect of various doses of minor tranquilizers on plasma corticosteroids in stressed rats.

R. Lahti, C. Barsuhn, 1975, Research communications in chemical pathology and pharmacology.

Biochemical, functional and behavioral evaluation of a series of novel antipsychotic-like agents.

R. Lahti, V. Sethy, P. von Voigtlander, 1983, Archives internationales de pharmacodynamie et de therapie.

The effect of antidepressants on L-5HTP-induced changes in rat plasma corticosteroids.

R. Lahti, C. Barsuhn, 1980, Research communications in chemical pathology and pharmacology.

Pharmacologic properties of (−)-3PPP (preclamol) in man

C. Tamminga, A. Carlsson, N. Cascella, 2005, Journal of Neural Transmission / General Section JNT.

A GC-MS Procedure for the Measurement of Dopamine in Mouse Striatal Tissue

R. Lahti, D. Duchamp, M. Ihnat, 1974 .

Regional expression of RGS4 mRNA in human brain †

C. Tamminga, R. Roberts, M. Vogel, 2004, The European journal of neuroscience.

Effects of prior administration of steroids upon recovery from lethal sepsis.

A. Chang, L. Hinshaw, M. Lane, 1986, Surgery, gynecology & obstetrics.

Design and Structure/Conformation-Activity Studies of a Prototypic Corticotropin-Releasing Factor (CRF) Antagonist: Multiple Alanine Substitutions of CRF12-41

W. C. Krueger, D. Evans, C. Bannow, 1993 .

Naphtho and benzo analogues of the kappa opioid agonist trans-(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] benzeneacetamide.

R. Lahti, M. Smith, S. Mizsak, 1991, Journal of medicinal chemistry.

Dopamine D4 receptors in human postmortem brain tissue of normal and schizophrenic subjects. An [3]NGD-94-1 study

C. Tamminga, R. Roberts, R. Lahti, 1998, Schizophrenia Research.

Des-tyrosine1-γ-endorphin increases the antinociceptive efficacy of morphine in the rat

G. Lindeberg, L. Terenius, R. Lahti, 1981 .